New combo aims to tame HPV throat cancer with fewer side effects
NCT ID NCT07578467
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether a new drug (ATRN-119) combined with a single, precise dose of radiation to the neck can safely and effectively treat early-stage HPV-positive throat cancer before surgery. About 35 participants will take the drug daily for 10 days and receive one radiation treatment on day 3, followed by standard surgery. The goal is to reduce long-term side effects while keeping cure rates high.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATRN-119 (a drug that blocks a DNA repair protein called ATR) plus a single dose of highly targeted radiation (SBRT) to the neck lymph nodes
What this could lead to
If it works, this approach could offer a less toxic treatment option for early-stage HPV-positive throat cancer, potentially reducing long-term side effects while keeping cure rates high.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply to everyone. The drug-radiation combo could cause unexpected side effects or fail to improve outcomes over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••